exenatide + Placebo
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Obesity
Conditions
Obesity, Impaired Glucose Tolerance
Trial Timeline
Apr 1, 2007 → Sep 1, 2010
NCT ID
NCT00456885About exenatide + Placebo
exenatide + Placebo is a approved stage product being developed by Eli Lilly for Obesity. The current trial status is completed. This product is registered under clinical trial identifier NCT00456885. Target conditions include Obesity, Impaired Glucose Tolerance.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (12)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01140893 | Phase 2/3 | UNKNOWN |
| NCT01364584 | Pre-clinical | Completed |
| NCT00845507 | Approved | Completed |
| NCT00603239 | Phase 3 | Completed |
| NCT00516074 | Phase 3 | Completed |
| NCT00500370 | Phase 2 | Completed |
| NCT00456885 | Approved | Completed |
| NCT00667732 | Approved | Completed |
| NCT00375492 | Phase 3 | Completed |
| NCT00324363 | Phase 3 | Completed |
| NCT00241423 | Phase 2 | Completed |
| NCT00099320 | Phase 3 | Completed |
Competing Products
20 competing products in Obesity
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| MK0493 | Merck | Phase 2 | 52 |
| MK0557 | Merck | Phase 3 | 77 |
| AMG 786 | Amgen | Phase 1 | 32 |
| Bimagrumab + Tirzepatide + Bimagrumab Placebo + Tirzepatide Placebo | Eli Lilly | Phase 2 | 52 |
| Tirzepatide | Eli Lilly | Phase 2 | 52 |
| Brenipatide | Eli Lilly | Phase 1 | 33 |
| Orforglipron + Placebo | Eli Lilly | Phase 3 | 77 |
| TERN-601 | Terns Pharmaceuticals | Phase 2 | 49 |
| MBX 4291 + Placebo | MBX Biosciences | Phase 1 | 28 |
| PG-102 | Rani Therapeutics | Phase 1 | 25 |
| Orforglipron + Placebo | Eli Lilly | Phase 1 | 33 |
| Tirzepatide + Placebo | Eli Lilly | Phase 3 | 77 |
| Eloralintide + Placebo | Eli Lilly | Phase 1 | 33 |
| Oral Azelaprag (BGE-105) + Oral Placebo for Azelaprag (BGE-105) + Tirzepatide + Tirzepatide Placebo | Eli Lilly | Phase 2 | 52 |
| LY3437943 + Midazolam + Warfarin + Caffeine | Eli Lilly | Phase 1 | 33 |
| Nimacimab injection + Nimacimab placebo injection + Nimacimab 300 mg injection | Skye Bioscience | Phase 2 | 44 |
| Tirzepatide | Eli Lilly | Approved | 85 |
| Adenosine + Regadenoson | Astellas Pharma | Pre-clinical | 23 |
| Micafungin + Micafungin | Astellas Pharma | Approved | 85 |
| Micafungin | Astellas Pharma | Approved | 85 |